Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Gains from Investment Securities (2019 - 2025)

Historic Gains from Investment Securities for Korro Bio (KRRO) over the last 7 years, with Q3 2025 value amounting to $1.2 million.

  • Korro Bio's Gains from Investment Securities rose 15773.42% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 million, marking a year-over-year increase of 7451.19%. This contributed to the annual value of $3.1 million for FY2024, which is 258.56% up from last year.
  • According to the latest figures from Q3 2025, Korro Bio's Gains from Investment Securities is $1.2 million, which was up 15773.42% from $2.3 million recorded in Q2 2025.
  • Korro Bio's Gains from Investment Securities' 5-year high stood at $9.0 million during Q1 2021, with a 5-year trough of $37000.0 in Q1 2022.
  • In the last 5 years, Korro Bio's Gains from Investment Securities had a median value of $1.2 million in 2025 and averaged $3.0 million.
  • In the last 5 years, Korro Bio's Gains from Investment Securities tumbled by 9958.69% in 2022 and then skyrocketed by 191081.08% in 2023.
  • Over the past 5 years, Korro Bio's Gains from Investment Securities (Quarter) stood at $283000.0 in 2021, then skyrocketed by 712.01% to $2.3 million in 2022, then tumbled by 68.06% to $734000.0 in 2023, then skyrocketed by 32.43% to $972000.0 in 2024, then increased by 21.71% to $1.2 million in 2025.
  • Its Gains from Investment Securities stands at $1.2 million for Q3 2025, versus $2.3 million for Q2 2025 and $501000.0 for Q1 2025.